Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

Ozanimod

Ozanimod Structure
  • ₹0
  • Product name: Ozanimod
  • CAS: 1306760-87-1
  • MF: C23H24N4O3
  • MW: 404.46
  • EINECS:814-246-9
  • MDL Number:MFCD28386168
  • Synonyms:Benzonitrile, 5-[3-[(1S)-2,3-dihydro-1-[(2-hydroxyethyl)aMino]-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-Methylethoxy)- (free base);Ozanimod;Benzonitrile, 5-[3-[(1S)-2,3-dihydro-1-[(2-hydroxyethyl)amino]-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)-;5-[3-[(1S)-2,3-Dihydro-1-[(2-hydroxyethyl)amino]-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile;oxanimod(RPC1063);RPC1063 Ozanimod;CS-2386;RPC1063;RPC-1063;RPC 1063
Manufacturer Product number Product description Packaging Price Updated Buy

Properties

Melting point :134-137°C
Boiling point :648.3±65.0 °C(Predicted)
Density :1.30±0.1 g/cm3(Predicted)
storage temp. :-20°C Freezer
solubility :DMSO (Slightly), Methanol (Slightly)
form :Solid
pka :14.73±0.10(Predicted)
color :White to Off-White
InChIKey :XRVDGNKRPOAQTN-FQEVSTJZSA-N
SMILES :C(#N)C1=CC(C2ON=C(C3=CC=CC4=C3CC[C@@H]4NCCO)N=2)=CC=C1OC(C)C

Safety Information

Symbol(GHS): GHS hazard pictograms
Signal word: Danger
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H372 Causes damage to organs through prolonged or repeated exposure Specific target organ toxicity, repeated exposure Category 1 Danger GHS hazard pictograms P260, P264, P270, P314, P501
Precautionary statements:
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P264 Wash hands thoroughly after handling.
P264 Wash skin thouroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P314 Get medical advice/attention if you feel unwell.
P501 Dispose of contents/container to..…

Description

Ozanimod is a sphingosine-1-phosphate receptor 1 (S1P1) and S1P5 agonist. It induces GTPγS binding in cell membranes expressing human S1P1 or S1P5 (EC50s = 0.41 and 11 nM, respectively) but not cell membranes expressing S1P2 or S1P3 receptors (EC50s = >10,000 nM for both). Ozanimod (0.2 mg/kg) reduces the number of peripheral lymphocytes in rats. It reduces disease severity and the number of circulating lymphocytes in a mouse model of experimental autoimmune encephalomyelitis (EAE). Ozanimod (0.3 and 1 mg/kg) reduces disease severity and body weight loss in a mouse model of TNBS-induced colitis. Formulations containing ozanimod have been used in the treatment of relapsing multiple sclerosis and ulcerative colitis.

Related product price